Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-05-31
2005-05-31
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
active
06899883
ABSTRACT:
The present invention provides a method of treating insulin-requiring diabetes in a mammal comprising the subcutaneous administration of an effective amount of a glucagon-like peptide 1-related peptide.
REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 0044168 (1982-01-01), None
patent: 708179 (1996-04-01), None
patent: 94 09496.8 (1994-05-01), None
patent: WO 90/11296 (1989-03-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO93/18786 (1993-09-01), None
patent: 93/18786 (1993-09-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
Kumar et al., P.N.A.S. USA, vol. 87:1337-1341, Feb. 1990.*
Gutniak et al., N.E.J.M., vol. 326: 1316-1322, May 1992.*
D'Alessio et al. J.C.I. vol. 93: 2263-2266, May 1994.*
Ngo, The Protein Folding Problem and Tertiam, Structure Prediction, 1994, Merz et al. (ed.) Binkhauser, Boston pp. 433, 492-495.*
Goth, Medical Pharmacology, Principles and Concepts Mosby Co. St Louis p. 184 pp. 19-20, 1984.*
Stedman's Medical Dictionary 24thEdition Williams & Wilkins, pp. 34 & 60, 1988.*
Andrews, et al, “Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas,”Journal of Biological Chemistry260:3910-3914 (1985).
Bell, et al, “Hamster preproglucagon contains the sequence of glucagon and two related peptides,”Nature302:716-718 (1983).
D'Alessio, D.A., et al. “Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,”J. Clin. Invest.,93:2263-2266 (1994).
Faloona, G.R., et al, inMethods of Hormone Radioimmunoassay,Unger, B.M. (eds), Academic Press, NY, pp. 317-330 (1974).
Ghiglione, et al, “How Glucagon-Like is Glucagon-Like peptide?”Diabetologia27:599-600 (1984).
Goth,Medical Pharmacology: Principles and Concepts,Mosby Co., St. Louis, pp. 19-20 (1984).
Gutniak, M., et al, “Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus,”New England Journal of Medicine326(20):1316-1322 (1992).
Kreymann, B., et al, “Glucagon-like peptide-1 7-36: A physiological incretin in man,”Lancet2:1300-1304 (1987).
Kumar, V., et al, “Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis,”Proc. Natl. Acad. Sci.87:1337-1341 (1990).
Nathan, D.M., et al, “Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects,”Diabetes Care15:270-276 (1992).
Ngo, J.T., inThe Protein Folding Problem and Tertiary Structure Prediction,Merz (ed), Birkhauser Boston, pp. 492-495 (1992).
Schmidt, et al, “Glucagon-Like peptide-1 but not Glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets,”Diabetologia28:704-707 (1985).
Uttenthal, et al, “Molecular forms of Glucagon-like peptide-1 in human pancreas and Glucagonomas,”The Journal of Clinical Endocrinology and Metabolism61:472-479 (1985).
Wettergren, et al, “Trucated GLP-1 (Proglucagon 78-107-Amide) inhibits gastric and pacreatic functions in man,”Dig Dis Sci38:665-673 (1993).
Gutniak et al., “Antidiabetogenic Effect of Glucagon-like Peptide-1 (7-36)Amide In Normal Subjects and Patients with Diabetes Mellitus,”N.E.J.M.326:1316 (1992).
Wettergren et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Digestive Diseases and Sciences38:665 (1993).
Fehmann, et al., “Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells,”Endocrinology,130(1):159-66 (1992).
Gromada, et al., “Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting βTC3 Cells: Role of PKA-independent Mechanisms, ”Brit. Jour. Phar.,118:769-75 (1996).
Gromada, et al., “Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1,”Eur. J. Physiol.,435:583-94 (1998).
Jones, et al., “Effects of Fedotozine on Gastric Emptying and Upper Gastrointestinal Symptoms in Diabetic Gastroparesis,”Ailment. Pharmacol. Ther.,14:937-43 (2000).
London Health Sciences Centre
Nolan Patrick J.
Sim & McBurney
LandOfFree
Treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460277